{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:52:36Z","timestamp":1791978756379,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102663","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:45:30Z","timestamp":1788677130000},"page":"102663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-5084","authenticated-orcid":false,"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-9465","authenticated-orcid":false,"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-2627","authenticated-orcid":false,"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-7458","authenticated-orcid":false,"given":"Bart","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Zieschang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102663_bib0001","unstructured":"World Health Organization, Global cancer observatory. Available at: https:\/\/gco.iarc.fr, 2024. Accessed: August 18, 2026."},{"issue":"1","key":"10.1016\/j.clgc.2026.102663_bib0002","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102663_bib0003","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102663_bib0004","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/OP.23.00346","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update: ASCO guideline Q and A","volume":"19","author":"Virgo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clgc.2026.102663_bib0005","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al., EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Available at: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf, 2024 Accessed: August 18, 2026."},{"issue":"2","key":"10.1016\/j.clgc.2026.102663_bib0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102663_bib0007","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102663_bib0008","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2026.102663_bib0009","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102663_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clgc.2020.08.008","article-title":"Resetting the bar of castration resistance: understanding androgen dynamics in therapy resistance and treatment choice in prostate cancer","volume":"19","author":"Shore","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102663_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659135","article-title":"Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies","volume":"11","author":"Wenzel","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102663_bib0012","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"issue":"10336","key":"10.1016\/j.clgc.2026.102663_bib0013","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2026.102663_bib0014","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clgc.2026.102663_bib0015","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2026.102663_bib0016","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102663_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"7 Suppl","key":"10.1016\/j.clgc.2026.102663_bib0018","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102663_bib0019","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102663_bib0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102663_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"},{"issue":"36","key":"10.1016\/j.clgc.2026.102663_bib0022","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102663_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clgc.2026.102663_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17425255.2025.2478167","article-title":"Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage","volume":"21","author":"Ibanez","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clgc.2026.102663_bib0025","series-title":"Analysis of population pharmacokinetics and exposure-response of darolutamide on prostate-specific antigen in patients with non-metastatic\/metastatic castration-resistant and metastatic hormone-sensitive prostate cancer","year":"2026"},{"issue":"5","key":"10.1016\/j.clgc.2026.102663_bib0026","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/mol.118.114314","article-title":"Organic anion transporting polypeptides: emerging roles in cancer pharmacology","volume":"95","author":"Schulte","year":"2019","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102663_bib0027","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02353487","article-title":"A population pharmacokinetic model for docetaxel (Taxotere\u00ae): model building and validation","volume":"24","author":"Bruno","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.clgc.2026.102663_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","article-title":"The combination of enzalutamide and opioids: a painful pitfall?","volume":"75","author":"Benoist","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102663_bib0029","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug\u2013drug interaction potential in men treated with enzalutamide: mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clgc.2026.102663_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116264","article-title":"Use of concomitant G-CSF in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: a phase III study","volume":"236","author":"Ong","year":"2026","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102663_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215576","article-title":"Early neutropenia on day 8 treated with adjuvant docetaxel-based chemotherapy in early breast cancer patients: putative mechanisms within the neutrophil pool system","volume":"14","author":"Furuya","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.clgc.2026.102663_bib0032","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102663_bib0033","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","article-title":"Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study","volume":"69","author":"Massard","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102663_bib0034","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.euf.2017.01.015","article-title":"Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-na\u00efve and CYP17 inhibitor-na\u00efve patients: follow-up from the ARADES and ARAFOR trials","volume":"4","author":"Shore","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.clgc.2026.102663_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102663_bib0036","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.clgc.2026.102663_bib0037","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102663_bib0038","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ijc.34922","article-title":"Darolutamide does not interfere with OATP-mediated uptake of docetaxel","volume":"155","author":"Buck","year":"2024","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2026.102663_bib0039","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-022-01159-6","article-title":"Influence of darolutamide on cabazitaxel systemic exposure","volume":"61","author":"Buck","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clgc.2026.102663_bib0040","unstructured":"ClinicalTrials.gov, Docetaxel or cabazitaxel with or without darolutamide in mCRPC (DAROTAXEL). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05762536, Accessed: August 18, 2026."},{"issue":"4","key":"10.1016\/j.clgc.2026.102663_bib0041","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10557-023-07453-0","article-title":"Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information","volume":"38","author":"Boujonnier","year":"2024","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:44Z","timestamp":1791977564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S1558767326001631"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102663","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102663"}}